Wealth Enhancement Advisory Services’s Compass Therapeutics CMPX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$195K	Buy	+83,567	New	+$247K	﹤0.01%	3608

Other funds holding CMPX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Wealth Enhancement Advisory Services's CMPX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Compass Therapeutics (CMPX) in Q2 2026: 83,567 shares worth $195K. The stake represents ﹤0.01% of the portfolio and ranks #3608 among its holdings.

215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

Wealth Enhancement Advisory Services held 83,567 shares of Compass Therapeutics worth $195K as of Q2 2026.
Compass Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
Compass Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3608 holding.
215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.